Charlotte Gils
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Charlotte Gils has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Mads Nybo
Department of Clinical Biochemistry , Odense University Hospital , Odense , Denmark
8 shared publications- Mads Nybo
Department of Clinical Biochemistry, Odense University Hospital
5 shared publications - Anton Pottegård
Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health University of Southern Denmark Odense Denmark
2 shared publications - Per Damkier
Department of Clinical Pharmacology Odense University Hospital Odense Denmark
2 shared publications - Pernille Just Vinholt
Department of Clinical Biochemistry Odense University Hospital Odense Denmark
2 shared publications Aina Jansen
Department of Clinical Biochemistry, Innlandet Hospital Trust, Lillehammer, Norway
1 shared publication
Latest Publications
- 18 December 2025
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 48 (2) , 470-472
Incorrect Genotyping in a Hemochromatosis Patient Heterozygous for HFE C282Y and Q283P Variants
- 18 December 2025
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 48 (2) , 470-472
Incorrect Genotyping in a Hemochromatosis Patient Heterozygous for HFE C282Y and Q283P Variants
- Open Access
- 11 December 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (5) , 972-978
Knowledge among clinical personnel on the impact of hemolysis using blood gas analyzers
Objectives: In the light of a rapidly increasing use of POCT blood gas testing, where tests and interpretation are performed by non-laboratory personnel, the objective was to investigate the knowledge among personnel in the Nordic countries using blood gas analyzers with focus on the interference from hemolysis. Methods: Information was obtained from a self-developed, pre-tested online questionnaire. The questions covered demographic information about the respondents and specific questions on handling of and knowledge about blood gas analyses and the impact of hemolysis. The questionnaire was distributed by e-mail to relevant colleagues on behalf of the Nordic preanalytical scientific working group under the Nordic Federation of Clinical Chemistry. Results: A total of 117 respondents completed the questionnaire. 62.7 % respondents both used the analyzer and interpreted the results. 59.6 % respondents did not know to which degree the blood gas analyzer can identify hemolysis. 4.4 % answered that all levels or high levels of hemolysis can be detected. 3.9 % considered the result valid despite hemolysis if it is released from the instrument. 73.7 % of all respondents knew that hemolysis alters potassium measurements, while knowledge about the effect on PaO2 and bicarbonate measurements were more divergent. Conclusions: The knowledge about blood gas analyzers with focus on the interference from hemolysis is sparse among non-laboratory personnel using the blood gas analyzers. This emphasizes the need for better education and competence management, which perhaps is even more important for these analyses than for other point-of-care tests.
- 11 December 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (5) , 972-978
Open AccessKnowledge among clinical personnel on the impact of hemolysis using blood gas analyzers
Objectives: In the light of a rapidly increasing use of POCT blood gas testing, where tests and interpretation are performed by non-laboratory personnel, the objective was to investigate the knowledge among personnel in the Nordic countries using blood gas analyzers with focus on the interference from hemolysis. Methods: Information was obtained from a self-developed, pre-tested online questionnaire. The questions covered demographic information about the respondents and specific questions on handling of and knowledge about blood gas analyses and the impact of hemolysis. The questionnaire was distributed by e-mail to relevant colleagues on behalf of the Nordic preanalytical scientific working group under the Nordic Federation of Clinical Chemistry. Results: A total of 117 respondents completed the questionnaire. 62.7 % respondents both used the analyzer and interpreted the results. 59.6 % respondents did not know to which degree the blood gas analyzer can identify hemolysis. 4.4 % answered that all levels or high levels of hemolysis can be detected. 3.9 % considered the result valid despite hemolysis if it is released from the instrument. 73.7 % of all respondents knew that hemolysis alters potassium measurements, while knowledge about the effect on PaO2 and bicarbonate measurements were more divergent. Conclusions: The knowledge about blood gas analyzers with focus on the interference from hemolysis is sparse among non-laboratory personnel using the blood gas analyzers. This emphasizes the need for better education and competence management, which perhaps is even more important for these analyses than for other point-of-care tests.
- Open Access
- 21 August 2024
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (10) , 4285-4294
Venous thromboembolism risk in adults with hereditary thrombophilia: a systematic review and meta-analysis
This systematic review and meta-analysis assesses venous thromboembolism (VTE) risk in adults with hereditary thrombophilia, including Factor V Leiden (FVL) mutation, prothrombin G20210A (FII) mutation, compound heterozygosity, protein C (PC), protein S (PS), and antithrombin (AT) deficiency. Eligibility criteria included studies suitable for quantitative synthesis with extractable information on VTE risk in adults (> 15 years). There were no restrictions on VTE type, location, or occurrence. Two authors reviewed all studies and extracted data from 107 publications, encompassing 107,130 individuals (21,560 experiencing VTE). We used a random effects model and calculated odds ratios (ORs) with 95% confidence intervals (CIs). The highest risk was associated with homozygous FVL (OR 5.58, 95% CI 4.61–6.74), homozygous FII (OR 5.16, 95% CI 3.12–8.52), and compound heterozygosity (OR 4.64, 95% CI 2.25–9.58). In contrast, VTE risk was lowest for FVL heterozygosity (OR 2.97, 95% CI 2.41–3.67) and FII heterozygosity (OR 2.21, 95% CI 1.70–2.87), whereas PC (OR 3.23, 95% CI 2.05–5.08), PS (OR 3.01, 95% CI 2.26–4.02), and AT deficiency (OR 4.01, 95% CI 2.50–6.44) demonstrated an intermediate VTE risk. These results highlight an increased risk of venous thromboembolism in adults with hereditary thrombophilia. However, the risk for patients with PC, PS, and AT deficiency appears to be lower than previously stated, likely due to varying thrombogeneity of the underlying genetic mutations. Further research addressing this aspect of VTE risk in hereditary thrombophilia is imperative to improve patient management. Trial registration: PROSPERO registration number CRD42022376757.
- 21 August 2024
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (10) , 4285-4294
Open AccessVenous thromboembolism risk in adults with hereditary thrombophilia: a systematic review and meta-analysis
This systematic review and meta-analysis assesses venous thromboembolism (VTE) risk in adults with hereditary thrombophilia, including Factor V Leiden (FVL) mutation, prothrombin G20210A (FII) mutation, compound heterozygosity, protein C (PC), protein S (PS), and antithrombin (AT) deficiency. Eligibility criteria included studies suitable for quantitative synthesis with extractable information on VTE risk in adults (> 15 years). There were no restrictions on VTE type, location, or occurrence. Two authors reviewed all studies and extracted data from 107 publications, encompassing 107,130 individuals (21,560 experiencing VTE). We used a random effects model and calculated odds ratios (ORs) with 95% confidence intervals (CIs). The highest risk was associated with homozygous FVL (OR 5.58, 95% CI 4.61–6.74), homozygous FII (OR 5.16, 95% CI 3.12–8.52), and compound heterozygosity (OR 4.64, 95% CI 2.25–9.58). In contrast, VTE risk was lowest for FVL heterozygosity (OR 2.97, 95% CI 2.41–3.67) and FII heterozygosity (OR 2.21, 95% CI 1.70–2.87), whereas PC (OR 3.23, 95% CI 2.05–5.08), PS (OR 3.01, 95% CI 2.26–4.02), and AT deficiency (OR 4.01, 95% CI 2.50–6.44) demonstrated an intermediate VTE risk. These results highlight an increased risk of venous thromboembolism in adults with hereditary thrombophilia. However, the risk for patients with PC, PS, and AT deficiency appears to be lower than previously stated, likely due to varying thrombogeneity of the underlying genetic mutations. Further research addressing this aspect of VTE risk in hereditary thrombophilia is imperative to improve patient management. Trial registration: PROSPERO registration number CRD42022376757.
- Open Access
- 30 May 2023
- Published by Elsevier in Clinica Chimica Acta
- Vol. 546, 117414
The impact of inter-laboratory glucose bias on the diagnosis of gestational diabetes mellitus: Comparison of common automated central laboratory methods
- 30 May 2023
- Published by Elsevier in Clinica Chimica Acta
- Vol. 546, 117414
Open AccessThe impact of inter-laboratory glucose bias on the diagnosis of gestational diabetes mellitus: Comparison of common automated central laboratory methods
- Open Access
- 5 January 2023
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 61 (8) , 1497-1505
Elevated Hemolysis Index is associated with higher risk of cardiovascular diseases
Objectives: In vivo hemolysis is associated with thromboembolism. Although an increased Hemolysis Index (HI) can be due to in vitro as well as in vivo hemolysis, both reflects a more fragile erythrocyte population. We therefore hypothesized that HI above upper reference limit would be associated with an increased risk of cardiovascular disease (CVD). Methods: We identified persons with two elevated HI (HI+) from blood samples analyzed at a university hospital laboratory from 2012 to 2017. We compared their risk of CVD with the risk in matched comparators with normal HI and from the general population. HI+ persons and comparators were followed from start date (date of the second elevated HI) until the first of the main outcome: CVD, emigration, death, or end of observation time on December 31, 2018. Results: In 43,102 unique HI+ persons, the risk of developing CVD was 40% higher compared with the general population and 13% higher compared with the matched blood sample cohort. HI+ was associated with a significantly increased cumulative incidence of both arterial and venous CVD compared with the matched blood sample cohort and the general population (respectively 47 and 14% for arterial CVD; 78 and 24% for venous CVD). Moreover, overall mortality risk was significantly higher in patients with HI+ than in the two comparator groups. Conclusions: Elevated HI is associated with increased risk of arterial and venous CVD and with increased mortality. Our findings imply that HI may contribute as a CVD risk biomarker.
- 5 January 2023
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 61 (8) , 1497-1505
Open AccessElevated Hemolysis Index is associated with higher risk of cardiovascular diseases
Objectives: In vivo hemolysis is associated with thromboembolism. Although an increased Hemolysis Index (HI) can be due to in vitro as well as in vivo hemolysis, both reflects a more fragile erythrocyte population. We therefore hypothesized that HI above upper reference limit would be associated with an increased risk of cardiovascular disease (CVD). Methods: We identified persons with two elevated HI (HI+) from blood samples analyzed at a university hospital laboratory from 2012 to 2017. We compared their risk of CVD with the risk in matched comparators with normal HI and from the general population. HI+ persons and comparators were followed from start date (date of the second elevated HI) until the first of the main outcome: CVD, emigration, death, or end of observation time on December 31, 2018. Results: In 43,102 unique HI+ persons, the risk of developing CVD was 40% higher compared with the general population and 13% higher compared with the matched blood sample cohort. HI+ was associated with a significantly increased cumulative incidence of both arterial and venous CVD compared with the matched blood sample cohort and the general population (respectively 47 and 14% for arterial CVD; 78 and 24% for venous CVD). Moreover, overall mortality risk was significantly higher in patients with HI+ than in the two comparator groups. Conclusions: Elevated HI is associated with increased risk of arterial and venous CVD and with increased mortality. Our findings imply that HI may contribute as a CVD risk biomarker.
- 21 September 2020
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 80 (7) , 580-589
Verification of the hemolysis index measurement: imprecision, accuracy, measuring range, reference interval and impact of implementing analytically and clinically derived sample rejection criteria
Automated spectrophotometric measurement of hemolysis index (HI) allows rapid and cost-effective assessment of hemolysis interference. We evaluated the analytical performance of HI on two different platforms. Further, the impact of implementing analytically and clinically derived sample rejection criteria was investigated. Precision profiles were established, and analytical error was assessed by comparison with the reference method for hemoglobin measurement on Architect c8000/c16000 (Abbott) and Cobas c702 (Roche Diagnostics) instruments. The impact of a more analyte-specific cut off based on analytical and biologival variation was examined for five hemolysis-sensitive plasma analyses according to European recommendations. Lastly, a reference interval was established for the HI on Cobas, using the CLSI C28A3c nonparametric method. Imprecision for HI of 0.6-3.0 % for Architect and 1.5-4.5 % for Cobas was considered acceptable, which also applied for trueness in the measuring tange > 2 g/L. If cutoffs based on analytical and biological variation were used to manage results from hemolyzed samples, more potassium, LDH, conjugated bilirubin and phosphate results would be suppressed. Considering RCV only LDS remained sensitive to hemolysis. The Cobas-based HI reference interval was established to 0.01–0.16 g/L. Thorough verification of the HI on two different clinical chemistry analyzers reveals acceptable analytical performance. HI cutoffs suggested by manufacturers may be optimized by clinical laboratories using analytical and/or biological variation. A reference interval for the HI analysis is relevant as the analysis has been suggested as a diagnostic tool in the assessment of in vivo hemolysis.
- 21 September 2020
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 80 (7) , 580-589
Verification of the hemolysis index measurement: imprecision, accuracy, measuring range, reference interval and impact of implementing analytically and clinically derived sample rejection criteria
Automated spectrophotometric measurement of hemolysis index (HI) allows rapid and cost-effective assessment of hemolysis interference. We evaluated the analytical performance of HI on two different platforms. Further, the impact of implementing analytically and clinically derived sample rejection criteria was investigated. Precision profiles were established, and analytical error was assessed by comparison with the reference method for hemoglobin measurement on Architect c8000/c16000 (Abbott) and Cobas c702 (Roche Diagnostics) instruments. The impact of a more analyte-specific cut off based on analytical and biologival variation was examined for five hemolysis-sensitive plasma analyses according to European recommendations. Lastly, a reference interval was established for the HI on Cobas, using the CLSI C28A3c nonparametric method. Imprecision for HI of 0.6-3.0 % for Architect and 1.5-4.5 % for Cobas was considered acceptable, which also applied for trueness in the measuring tange > 2 g/L. If cutoffs based on analytical and biological variation were used to manage results from hemolyzed samples, more potassium, LDH, conjugated bilirubin and phosphate results would be suppressed. Considering RCV only LDS remained sensitive to hemolysis. The Cobas-based HI reference interval was established to 0.01–0.16 g/L. Thorough verification of the HI on two different clinical chemistry analyzers reveals acceptable analytical performance. HI cutoffs suggested by manufacturers may be optimized by clinical laboratories using analytical and/or biological variation. A reference interval for the HI analysis is relevant as the analysis has been suggested as a diagnostic tool in the assessment of in vivo hemolysis.
- 5 March 2020
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 5 (3) , 599-601
A Reference Interval for Icteric Index for Possible Clinical Use of the Analysis
- 5 March 2020
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 5 (3) , 599-601
A Reference Interval for Icteric Index for Possible Clinical Use of the Analysis
- 1 February 2020
- Published by Elsevier in Clinica Chimica Acta
- Vol. 501, 83-84
Lipemia Index and screening for hyperlipidemia – A diagnostic opportunity?
- 1 February 2020
- Published by Elsevier in Clinica Chimica Acta
- Vol. 501, 83-84
Lipemia Index and screening for hyperlipidemia – A diagnostic opportunity?
- 30 December 2019
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 5 (1) , 83-90
Quality Control of Preanalytical Handling of Blood Samples for Future Research: A National Survey
Background: Assessment and control of preanalytical handling of blood samples for future research are essential to preserve integrity and assure quality of the specimens. However, investigation is limited on how quality control of preanalytical handling of blood samples is performed by biobanks.Methods: A questionnaire was sent to all Danish departments of clinical biochemistry, all Danish departments of clinical immunology, the Danish Health Surveillance Institution and the Danish Cancer Society. The questionnaire consisted of questions regarding preanalytical handling of samples for future research. The survey was carried out from October 2018 until the end of January 2019.Results: A total of 22 departments (78%) replied, of which 17 (77%) performed preanalytical quality control of the blood samples. This quality control consisted of patient preparation, temperature surveillance of freezers, maintenance of centrifuges, and visual inspection for hemolysis, lipemia, and sample volume. Automated sample check for hemolysis, icterus, and lipemia interferences was performed by 41% of respondents, not performed by 50% of respondents, and 9% did not answer. The majority (55%) of the participants stated that they had no local standard operating procedure for preanalytical handling of samples for research projects.Conclusions: The preanalytical phase for blood samples obtained and preserved for future research in Denmark is highly heterogeneous, although many aspects (e.g., hemolysis, which also affects DNA analyses, metabolomics, and proteomics) seems highly relevant to document. Our findings emphasize the need to optimize and standardize best practices for the preanalytical phase for blood samples intended for use in future research projects.
- 30 December 2019
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 5 (1) , 83-90
Quality Control of Preanalytical Handling of Blood Samples for Future Research: A National Survey
Background: Assessment and control of preanalytical handling of blood samples for future research are essential to preserve integrity and assure quality of the specimens. However, investigation is limited on how quality control of preanalytical handling of blood samples is performed by biobanks.Methods: A questionnaire was sent to all Danish departments of clinical biochemistry, all Danish departments of clinical immunology, the Danish Health Surveillance Institution and the Danish Cancer Society. The questionnaire consisted of questions regarding preanalytical handling of samples for future research. The survey was carried out from October 2018 until the end of January 2019.Results: A total of 22 departments (78%) replied, of which 17 (77%) performed preanalytical quality control of the blood samples. This quality control consisted of patient preparation, temperature surveillance of freezers, maintenance of centrifuges, and visual inspection for hemolysis, lipemia, and sample volume. Automated sample check for hemolysis, icterus, and lipemia interferences was performed by 41% of respondents, not performed by 50% of respondents, and 9% did not answer. The majority (55%) of the participants stated that they had no local standard operating procedure for preanalytical handling of samples for research projects.Conclusions: The preanalytical phase for blood samples obtained and preserved for future research in Denmark is highly heterogeneous, although many aspects (e.g., hemolysis, which also affects DNA analyses, metabolomics, and proteomics) seems highly relevant to document. Our findings emphasize the need to optimize and standardize best practices for the preanalytical phase for blood samples intended for use in future research projects.
- Open Access
- 5 December 2019
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 58 (4) , 560-568
Use of clinical data and acceleration profiles to validate pneumatic transportation systems
Background: Modern pneumatic transportation systems (PTSs) are widely used in hospitals for rapid blood sample transportation. The use of PTS may affect sample integrity. Impact on sample integrity in relation to hemolysis and platelet assays was investigated and also, we wish to outline a process-based and outcome-based validation model for this preanalytical component. Methods: The effect of PTS was evaluated by drawing duplicate blood samples from healthy volunteers, one sent by PTS and the other transported manually to the core laboratory. Markers of hemolysis (potassium, lactate dehydrogenase [LD] and hemolysis index [HI]) and platelet function and activation were assessed. Historic laboratory test results of hemolysis markers measured before and after implementation of PTS were compared. Furthermore, acceleration profiles during PTS and manual transportation were obtained from a mini g logger in a sample tube. Results: Hand-carried samples experienced a maximum peak acceleration of 5 g, while peaks at almost 15 g were observed for PTS. No differences were detected in results of potassium, LD, platelet function and activation between PTS and manual transport. Using past laboratory data, differences in potassium and LD significantly differed before and after PTS installation for all three lines evaluated. However, these estimated differences were not clinically significant. Conclusions: In this study, we found no evidence of PTS-induced hemolysis or impact on platelet function or activation assays. Further, we did not find any clinically significant changes indicating an acceleration-dependent impact on blood sample quality. Quality assurance of PTS can be performed by surveilling outcome markers such as HI, potassium and LD.
- 5 December 2019
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 58 (4) , 560-568
Open AccessUse of clinical data and acceleration profiles to validate pneumatic transportation systems
Background: Modern pneumatic transportation systems (PTSs) are widely used in hospitals for rapid blood sample transportation. The use of PTS may affect sample integrity. Impact on sample integrity in relation to hemolysis and platelet assays was investigated and also, we wish to outline a process-based and outcome-based validation model for this preanalytical component. Methods: The effect of PTS was evaluated by drawing duplicate blood samples from healthy volunteers, one sent by PTS and the other transported manually to the core laboratory. Markers of hemolysis (potassium, lactate dehydrogenase [LD] and hemolysis index [HI]) and platelet function and activation were assessed. Historic laboratory test results of hemolysis markers measured before and after implementation of PTS were compared. Furthermore, acceleration profiles during PTS and manual transportation were obtained from a mini g logger in a sample tube. Results: Hand-carried samples experienced a maximum peak acceleration of 5 g, while peaks at almost 15 g were observed for PTS. No differences were detected in results of potassium, LD, platelet function and activation between PTS and manual transport. Using past laboratory data, differences in potassium and LD significantly differed before and after PTS installation for all three lines evaluated. However, these estimated differences were not clinically significant. Conclusions: In this study, we found no evidence of PTS-induced hemolysis or impact on platelet function or activation assays. Further, we did not find any clinically significant changes indicating an acceleration-dependent impact on blood sample quality. Quality assurance of PTS can be performed by surveilling outcome markers such as HI, potassium and LD.